Tenofovir Alafenamide Fumarate Patent Expiration
Tenofovir Alafenamide Fumarate is Used for treating chronic hepatitis B in adult and pediatric patients. It was first introduced by Gilead Sciences Inc
Tenofovir Alafenamide Fumarate Patents
Given below is the list of patents protecting Tenofovir Alafenamide Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vemlidy |
US8754065 (Pediatric) | Tenofovir alafenamide hemifumarate | Feb 15, 2033 | Gilead Sciences Inc |
| Vemlidy |
US9296769 (Pediatric) | Tenofovir alafenamide hemifumarate | Feb 15, 2033 | Gilead Sciences Inc |
| Vemlidy | US8754065 | Tenofovir alafenamide hemifumarate | Aug 15, 2032 | Gilead Sciences Inc |
| Vemlidy | US9296769 | Tenofovir alafenamide hemifumarate | Aug 15, 2032 | Gilead Sciences Inc |
| Vemlidy |
US7390791 (Pediatric) | Prodrugs of phosphonate nucleotide analogues |
Jul 07, 2025
(Expired) | Gilead Sciences Inc |
| Vemlidy | US7390791 | Prodrugs of phosphonate nucleotide analogues |
Jan 07, 2025
(Expired) | Gilead Sciences Inc |
| Vemlidy | US7803788 | Prodrugs of phosphonate nucoleotide analogues |
Feb 02, 2022
(Expired) | Gilead Sciences Inc |
Tenofovir Alafenamide Fumarate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List